Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy

Amir Ajoolabady, Yaguang Bi, David J. McClements, Gregory Y.H. Lip, Des R. Richardson, Russel J. Reiter, Daniel J. Klionsky, Jun Ren

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Atherosclerosis refers to a unique form of chronic proinflammatory anomaly of the vasculature, presented as rupture-prone or occlusive lesions in arteries. In advanced stages, atherosclerosis leads to the onset and development of multiple cardiovascular diseases with lethal consequences. Inflammatory cytokines in atherosclerotic lesions contribute to the exacerbation of atherosclerosis. Pharmacotherapies targeting dyslipidemia, hypercholesterolemia, and neutralizing inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17, and IL-12/23) have displayed proven promises although contradictory results. Moreover, adjuvants such as melatonin, a pluripotent agent with proven anti-inflammatory, anti-oxidative and neuroprotective properties, also display potentials in alleviating cytokine secretion in macrophages through mitophagy activation. Here, we share our perspectives on this concept and present melatonin-based therapeutics as a means to modulate mitophagy in macrophages and, thereby, ameliorate atherosclerosis.

Original languageEnglish (US)
Article number106072
JournalPharmacological Research
StatePublished - Feb 2022


  • Atherosclerosis
  • Macrophages
  • Melatonin
  • Mitophagy
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy'. Together they form a unique fingerprint.

Cite this